Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The etiopathogenesis and treatment of major mood disorders have historically focused on modulation of monoaminergic (serotonin, norepinephrine, dopamine) and amino acid [γ-aminobutyric acid (GABA), glutamate] receptors at the plasma membrane. Although the activation and inhibition of these receptors acutely alter local neurotransmitter levels, their neuropsychiatric effects are not immediately observed. This time lag implicates intracellular neuroplasticity as primary in the mechanism of action of antidepressants and mood stabilizers. The modulation of intracellular second messenger/signal transduction cascades affects neurotrophic pathways that are both necessary and sufficient for monoaminergic and amino acid–based treatments. In this review, we will discuss the evidence in support of intracellular mediators in the pathophysiology and treatment of preclinical models of despair and major depressive disorder (MDD). More specifically, we will focus on the following pathways: cAMP/PKA/CREB, neurotrophin-mediated (MAPK and others), p11, Wnt/Fz/Dvl/GSK3β, and NFκB/ΔFosB. We will also discuss recent discoveries with rapidly acting antidepressants, which activate the mammalian target of rapamycin (mTOR) and release of inhibition on local translation via elongation factor stimulation. Throughout this discourse, we will highlight potential intracellular targets for therapeutic intervention. Finally, future clinical implications are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 2×
“Autry et al.75 reported that subanesthetic doses of ketamine released inhibition of translation by deactivating eukaryotic elongation factor 2 kinase (eEF2K)/calcium-calmodulin protein kinase type III (CAMKIII) (Figure 3).”
BackgroundBrain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression
Shirayama, Y., Chen, A. C.-H., Nakagawa, S., Russell, D. S., & Duman, R. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03251.2002 · Cited by 1,654
Nibuya, M., Nestler, E., & Duman, R. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-07-02365.1996 · Cited by 1,206
The -Catenin Destruction Complex
Stamos, J. L., & Weis, W. I. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a007898 · Cited by 1,062 · cited 1×
“This releases b-catenin from the axin-adenosis polyposis coli-GSK-3b ‘‘destruction complex’’ for nuclear translocation.(57) Nuclear b-catenin interacts with the transcription factor T-cell factor/lymphoid enhancer factor (TCF/LEF) to express Wnt-responsive genes.”
BackgroundEssential role of brain-derived neurotrophic factor in adult hippocampal function
Monteggia, L. M., Barrot, M., Powell, C. M., Berton, O., Galanis, V., Gemelli, T., Meuth, S., Nagy, A., Greene, R. W., & Nestler, E. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402141101 · Cited by 685 · cited 1×
“Conditional BDNF knockout in the mouse forebrain impairs the antidepressant effects of desipramine on the forced swim test (FST).(20) As a result, CNS BDNF expression is both necessary (based on inducible knockout experiments) and sufficient (from exogenous administration experiments) for antidepressant efficacy.”
BackgroundAlterations in 5-HT 1B Receptor Function by p11 in Depression-Like States
Svenningsson, P., Chergui, K., Rachleff, I., Flajolet, M., Zhang, X., Yacoubi, M. E., Vaugeois, J.-M., Nomikos, G. G., & Greengard, P. (2006) · Science · doi:10.1126/science.1117571 · Cited by 572 · cited 3×
“The antidepressants imipramine and tranylcypromine as well as ECS increase neocortical p11 mRNA levels.(51) p11 knockout mice display biochemical, electrophysiological, and behavioral responses consistent with depression.”
BackgroundResultInfluentialFrenois, F., Moreau, M., O’Connor, J., Lawson, M., Micon, C., Lestage, J., Kelley, K. W., Dantzer, R., & Castanon, N. (2007) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2007.03.005 · Cited by 438
Zarate, C. A., Mathews, D., Ibrahim, L., Chaves, J. F., Marquardt, C., Ukoh, I., Jolkovsky, L., Brutsche, N. E., Smith, M. A., & Luckenbaugh, D. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.019 · Cited by 255 · cited 1×
“Glutamatebased antidepressants are more rapidly acting and have larger effect sizes in clinical trials.(79,80) Two of the most promising candidates for future drug development based on preclinical studies with ketamine are mTOR and eEF2K/eEF2.”
BackgroundSelf-citationHeine, V. M., Zareno, J., Maslam, S., Joëls, M., & Lucassen, P. J. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.03951.x · Cited by 225
Cited by
Migraine Triggers and Oxidative Stress: A Narrative Review and Synthesis
Borkum, J. M. (2016) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12725 · Cited by 280
Iadarola, N. D., Niciu, M. J., Richards, E. M., Vande Voort, J. L., Ballard, E. D., Lundin, N. B., Nugent, A. C., Machado-Vieira, R., & Zarate, C. A. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315579059 · Cited by 201
Self-citationClinical Predictors of Ketamine Response in Treatment-Resistant Major Depression
Niciu, M. J., Luckenbaugh, D. A., Ionescu, D. F., Guevara, S., Machado-Vieira, R., Richards, E. M., Brutsche, N. E., Nolan, N. M., & Zarate, C. A. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08698 · Cited by 165
Self-citationmiR-323a regulates ERBB4 and is involved in depression
Fiori, L. M., Kos, A., Lin, R., Théroux, J.-F., Lopez, J. P., Kühne, C., Eggert, C., Holzapfel, M., Huettl, R.-E., Mechawar, N., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00953-7 · Cited by 88
Ma, J., Wang, L., Yang, Y., Qiao, Z., Fang, D., Qiu, X., Yang, X., Zhu, X., He, J., Pan, H., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0170994 · Cited by 26
Metadata
- Authors
- Niciu, M. J., Ionescu, D. F., Mathews, D. C., Richards, E. M., & Zarate, C. A.
- Venue
- CNS Spectrums
- Publisher
- Cambridge University Press (CUP)
- Published
- 2013-03-05
- Volume
- 18
- Issue
- 5
- Pages
- 231-241
- ISSN
- 1092-8529 (ISSN-L)
- 2165-6509
- OpenAlex
- W2115910429
- Cited by
- 43
- References
- 21
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder. https://app.cochat.ai/papers/10.1017/s1092852913000059
- The paper
- Niciu, M. J., Ionescu, D. F., Mathews, D. C., Richards, E. M., & Zarate, C. A. (2013). Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder. CNS Spectrums. https://doi.org/10.1017/s1092852913000059
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.